Liraglutide Protocol
Dosing & Research
Last Updated: September 4, 2026
Chemical Identity
- Molecular Formula
- C172H265N43O51
- Molecular Weight
- 3751.20 g/mol
- CAS Number
- 204656-20-2
Glucose control, Weight-management research, Cardiometabolic studies, GLP-1 pharmacology
Half-Life
Approximately 13 Hours
Administration
Injection
Frequency
Daily
How It Works
- Glucose control
- Weight-management research
- Cardiometabolic studies
- GLP-1 pharmacology
Dosing Structure
Dose
0.6–3.0mg/day (titrated weekly)
Frequency
Daily
Notes
1x Daily titration: Week 1-2: 0.6mg/day | Week 3-4: 1.2mg/day | Week 5+: 1.8mg/day (up to 3.0mg for weight management research). No need to increase dose if experiencing benefits at a lower level. Inject: Thigh, abdomen, or upper arm (rotate sites). Follows a dose-titration protocol.
Example Protocols
Dose: 0.6–3.0mg/day (titrated weekly)
Frequency: Daily
Duration: Chronic Daily Treatment
Off Period: Not listed
Find Research Grade Liraglutide
Recommended vendors for sourcing research-grade material. PeptaBase does not sell peptides directly.
Vendor One Research Labs
COA VerifiedThird-party COA-verified research peptides with published batch testing.
Source Coming SoonVendor Two Sciences
Purity TestedUS-based research compound supplier with independent purity testing.
Source Coming SoonVendor Three Peptide Co.
Bulk research peptide sourcing with batch-level documentation.
Source Coming SoonProtocol Notes
1x Daily titration
Week 1-2: 0.6mg/dayWeek 3-4: 1.2mg/dayWeek 5+: 1.8mg/day (up to 3.0mg for weight management research)
•
No need to increase dose if experiencing benefits at a lower level.
•
Inject: Thigh, abdomen, or upper arm (rotate sites).
•
Follows a dose-titration protocol.
Research & Studies
Loading citations…
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.